About Precision NanoSystems’ Technology and Applications
Precision NanoSystems Inc. (PNI) empowers researchers to advance the application of nanoparticles in understanding and treating disease, particularly in genetic medicine.PNI’s nanoparticle technology enables the potent transfection of primary cells with high cell transfection efficiency (efficient nucleic acid delivery) achieved using lipid nanoparticles (LNPs). Furthermore, PNI’s versatile NanoAssemblr™ nanoparticle formulation platform enables rapid, reproducible, and scalable lipid nanoparticle and liposome formulation, as well as polymeric nanoparticle production.
The NanoAssemblr platform simplifies the formulation of nanoparticles to accelerate nanoparticle research from drug target discovery to therapeutic nanoparticle manufacturing for the clinic. For example, drug targets can be screened using NanoAssemblr Transfection Reagents prepared on the NanoAssemblr Spark™ at a microlitre scale. Armed with this knowledge, researchers can then optimize their genetic medicines, polymeric nanoparticles and liposomal encapsulation technologies at the millilitre scale using the NanoAssemblr Benchtop. For larger scale animal and early CMC studies, the NanoAssemblr Blaze™ uses the same process parameters optimized for LNP, polymer and liposome encapsulation developed on the Benchtop. The Blaze seamlessly scales nanoparticle formulations, further bridging the gap between nanoparticle discovery and clinical development. As a final step towards the clinic, process parameters can be transferred to the NanoAssemblr Scale-Up system, which is suitable for the GMP environment where LNP and polymer nanoparticles synthesis, or liposome manufacturing for clinical trials, can be accomplished.